Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
07 août 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2020 Financial Results and Provides Corporate Update
04 août 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
Arvinas Appoints Wendy Dixon, Ph.D., to its Board of Directors
29 juin 2020 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present Virtually at the BMO 2020 Prescriptions for Success Healthcare Conference
17 juin 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Appoints Linda Bain to its Board of Directors
11 juin 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present Virtually at the Goldman Sachs 41st Annual Global Healthcare Conference
05 juin 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Releases Updated Dose Escalation Data from Clinical Trial of PROTAC® Protein Degrader ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer
29 mai 2020 07h00 HE
|
Arvinas Inc.
- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Data represent the first demonstration of PROTAC®-mediated degradation...
Arvinas to Hold Virtual 2020 Annual Meeting of Stockholders
20 mai 2020 16h30 HE
|
Arvinas Inc.
NEW HAVEN, Conn., May 20, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Announces Updated Phase 1 Data Demonstrating Clinical Activity of PROTAC® Protein Degrader ARV-110 in Patients with Refractory Prostate Cancer
13 mai 2020 17h49 HE
|
Arvinas Inc.
- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of Clinical Oncology (ASCO)...
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
16 mars 2020 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., March 16, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...